FPD Fibroproliferative disorders HTS Hypertrophic scar(s)
TBSA Total burn surface area
SNP Single-nucleotide polymorphisms ECM Extracellular matrix
TGF-β Transforming growth factor beta MMP Matrix metalloproteinase
MMP-1 Matrix metalloproteinase 1 or collagenase α-SMA Alpha smooth muscle actin
CTGF Connective tissue growth factor HSP47 Heat shock protein 47
SLRP(s) Small leucine-rich repeated proteoglycan(s) TLRs Toll-like receptors
PAMPs Pathogen-associated molecular patterns DAMPs Damage-associated molecular patterns LPS Lipopolysaccharide
1.
IL Interleukin IFN Interferon
TRIF Toll/interleukin (IL)-1R domain-containing adaptor inducing IFN-β factor NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
MAPK Mitogen-activated protein kinase COL-I Type I collagen
COL-III Type III collagen
TNF-α Tumor necrosis factor alpha
PBMCs Peripheral blood mononuclear cells LSP-1 Leukocyte-specific protein 1
VEGF Vascular endothelial growth factor SDF-1 Stromal cell–derived factor 1 HO Heterotopic ossification Th T-helper cells
NK Natural killer
M1 Classically activated macrophages M2 Alternatively activated macrophages NOS Nitric oxide synthase
Arg-1 Arginase I
MCP-1 Monocyte chemotactic protein 1
NADPH Nicotinamide adenine dinucleotide phosphate NOX4 NADPH oxidase 4
ROS Reactive oxygen species
DMEM Dulbecco’s modified Eagle’s medium MRP1 Multidrug resistance–associated protein 1 CSS Cultured skin substitutes
C-GAG Collagen-glycosaminoglycan Ad Adenoviral
IGF Insulin-like growth factor
IGFBP Insulin-like growth factor–binding protein ERK Extracellular signal–regulated kinase LPA Lysophosphatidic acid
PDGF Platelet-derived growth factor LDI Laser Doppler imaging
si-RNA Small inhibitory messenger ribonucleic acid
REFERENCES
Lee DE, Trowbridge RM, Ayoub NT, et al. Group box protein-1, matrix metalloproteinases, and vitamin D in keloids and hypertrophic scars. Plast Reconstr Surg Glob Open.
2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 2015;3(6):e425.
Kozak L, Bacon W, Krzyzanowski M, et al. Vital and Health Statistics. Vol. 5 (ed. Office, GP); 2008.
Ladak A, Tredget EE. Pathophysiology and management of the burn scar. Clin Plast Surg. 2009;36(4):661–742.
Dissanaike S, Rahimi M. Epidemiology of burn injuries: highlighting cultural and socio- demographic aspects. Int Rev Psychiatry. 2009;21(6):505–119.
Ryan CM, Schoenfeld DA, Thorpe WP, et al. Objective estimates of the probability of death from burn injuries. N Engl J Med. 1998;338:362–366.
Tredget EE, Shankowsky HA, Taerum TV, et al. The role of inhalation injury in burn trauma. A Canadian experience. Ann Surg. 1990;212:720–727.
Snelling CF. Burn units’ share of Canada’s total burn care. J Burn Care Rehabil. 1995;16:519–524.
Armour A, Scott PG, Tredget EE. Cellular and molecular pathology of HTS: basis for treatment. Wound Repair Regen. 2007;15(suppl 1):S6–S17.
Engrav LH, Covey MH, Dutcher KD, et al. Impairment, time out of school, and time off from work after burns. Plast Reconstr Surg. 1987;79:927–934.
Helm P, Herndon DN, Delateur B. Restoration of function. Burn Care Res. 2007;28(4):611–614.
Butzelaar L, Soykam EA. Garre FG, et al. Going into surgery: risk factors for hypertrophic scarring. Wound Rep Reg. 2105;23:531–537.
Dunkin CS, Pleat JM, Gillespie PH, et al. Scarring occurs at a critical depth of skin injury: precise measurement in a graduated dermal scratch in human volunteers. Plast Reconstr Surg. 2007;119(6):1722–1733.
Jaskille AD, Shupp JW, Jordan MH, et al. Critical review of burn depth assessment techniques: Part I. Historical review. J Burn Care Res. 2009;30(6):937–947.
Bombaro KM, Engrav LH, Carrougher GJ, et al. What is the prevalence of hypertrophic scarring following burns? Burns. 2003;29:299–302.
Ripper S, Renneberg B, Landmann C, et al. Adherence to pressure garment therapy in adult burn patients. Burns. 2009;35(5):657–664.
Harte D, Gordon J, Shaw M, et al. The use of pressure and silicone in hypertrophic scar management in burns patients: a pilot randomized controlled trial. J Burn Care Res. 2009;30(4):632–642.
Brown JJ, Bayat A. Genetic susceptibility to raised dermal scarring. Br J Dermatol. 2009;161(1):8–18.
Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. Plast Reconstr Surg. 2010;125(2):557–568.
Thompson CM, Hocking AM, Honari S, et al. Genetic risk factors for hypertrophic scar development. J Burn Care Res. 2013;34(5):477–482.
Roeder RA, Schulman CI. An overview of war-related thermal injuries. J Craniofac Surg. 2010;21(4):971–975.
Kauvar DS, Wade CE, Baer DG. Burn hazards of the deployed environment in wartime: epidemiology of noncombat burns from ongoing United States military operations. J Am Coll Surg. 2009;209(4):453–460.
Esselman PC, Thombs BD, Magyar-Russell G, et al. Burn rehabilitation: state of the science. Am J Phys Med Rehabil 2006;85(4):383–413.
Stoddard FJ Jr, Ryan CM, Schneider JC. Physical and psychiatric recovery from burns. Psychiatr Clin North Am 2015;38(1):105–120.
24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45.
Scott PG, Dodd CM, Tredget EE, et al. Chemical characterization and quantification of proteoglycans in human post-burn hypertrophic and mature scars. Clin Sci. 1996;90:417– 425.
Lapiere CM, Nusgens B Pierard GE. Interaction between collagen type I and type III in conditioning bundles organization. Connect Tissue Res. 1977;5:21–29.
Linares HA, Kischer CW, Dorkovsky M, et al. The histiotypic organization of the hypertrophic scar in humans. J Invest Dermatol. 1972;59:323–331.
Scott PG, Dodd C, Tredget EE, et al. Immunohistochemical localization of the
proteoglycans decorin, biglycan and versican and transforming growth factor-β in human post-burn hypertrophic and mature scars. Histopathology. 1995;26:423–431.
Danielson KG, Baribault, H, Holmes DF, et al. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol. 1997;136:729–743. Sayani K, Dodd CM, Nedelec B, et al. Delayed appearance of decorin in healing burn scars. Histopathology. 2000;36:262–272.
Tredget EE, Nedelec B, Scott PG, et al. Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy. Surg Clin North Am. 1997;77(3):701–730.
Ghahary A, Shen YJ, Nedelec B, et al. Collagenase production is lower in post-burn
hypertrophic scar fibroblasts than in normal fibroblasts and is reduced by insulin-like growth factor-1. J Invest Dermatol. 1996;106(3):476–481.
Wang R, Ghahary A, Shen YJ, et al. Nitric oxide synthase expression and nitric oxide production are reduced in hypertropyic scar tissue and fibroablsts. J Invest Dermatol. 1997;108:438–444.
Scott PG, Dodd CM, Ghahary A, et al. Fibroblasts from post-burn hypertrophic scar tissue synthesize less decorin than normal dermal fibroblasts. Clin Sci (Lond). 1998;94:541–547. Nedelec B, Shankowsky H, Scott PG, et al. Myofibroblasts and apoptosis in human
hypertrophic scars: the effect of interferon-alpha2b. Surgery. 2001;130:798–808.
Nedelec B, Dodd CM, Scott PG, et al. Effect of interferon-alpha2b on guinea pig wound closure and the expression of cytoskeletal proteins in vivo. Wound Repair Regen.
1998;6:202–212.
Moulin V, Castilloux G, Auger FA, et al. Modulated response to cytokines of human wound healing myofibroblasts compared to dermal fibroblasts. Exp Cell Res. 1998;238:283–293. Ding J, Hori K, Zhang R, et al. Stromal cell-derived factor 1 (SDF-1) and its receptor CXCR4 in the formation of postburn hypertrophic scar (HTS). Wound Repair Regen. 2011;19(5):568–578.
Squier CA. The effect of stretching on formation of myofibroblasts in mouse skin. Cell Tiss Res. 1981;220:325–335.
Desmouliere A, Badid C, Bochaton-Piallat ML, et al. Apoptosis during wound healing, fibrocontractive diseases and vascular wall injury. Int J Biochem Cell Biol. 1997;29:19–30. Desmouliere A, Redard M, Darby I, et al. Apopotosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am J Pathol. 1995;146:56–66. Kwan P, Hori K, Ding J, et al. Scar and contracture: Hand Clin. 2009;25(4):511–528. Sorrell JM, Baber MA, Caplan AI. Clonal characterization of fibroblasts in the superficial layer of the adult human dermis. Cell Tissue Res. 2007;327:499–510.
Reynolds AJ, Jahoda CA. Inductive properties of hair follicle cells. Ann N Y Acad Sci. 1991;642:226–241.
Jahoda CA, Reynolds AJ. Dermal-epidermal interactions. Adult follicle-derived cell populations and hair growth. Dermatol Clin. 1996;14:573–583.
46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64.
skin are heterogeneous in expression of collagenase and types I and III procollagen mRNA. Wound Repair Regen. 2004;12;175–182.
Honardoust D, Varkey M, Hori K, et al. Small Leucine-rich proteoglycans, decorin and fibromodulin, are reduced in post-burn hypertrophic scar. Wound Healing Regen. 2011;19(3):368–378.
Wang J, Dodd C, Shankowsky H, et al. Deep dermal fibroblast may dictate hypertrophic scarring. Lab Invest 2008;88(12):1278–1290.
Scott PG, Dodd CM, Tredget EE, et al. Immunohistochemical localization of the
proteoglycans decorin, biglycan and versican and transforming growth factor-beta in human post-burn hypertrophic and mature scars. Histopathology. 1995;26:423–431.
Hildebrand A, Romarís M, Rasmussen LM, et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J. 1994;302(Pt 2):527–534.
Soo C, Hu FY, Zhang X, et al. Differential expression of fibromodulin, a transforming growth factor-beta modulator, in fetal skin development and scarless repair. Am J Pathol. 2000;157:423–433.
Kolb M, Margetts PJ, Sime PJ, et al. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol. 2001;280:1327–1334.
Mattoli S, Bellini A, Schmidt M. The role of a human hematopoietic mesenchymal
progenitor in wound healing and fibrotic diseases and implications for therapy. Curr Stem Cell Res Ther. 2009;4:266–280.
Honardoust D, Varkey M, Hori K, et al. Reduced decorin, fibromodullin and TGF-β3 in deep dermis lead to hypertrophic scar. J Burn Care Res. 2012;33(2):218–227.
Ding J, Ma ZS, Shankowsky HA, et al. Deep dermal fibroblast profibrotic characteristics are enhanced by bone marrow-derived mesenchymal stem cells (BM-MSCs). Wound Repair Regen. 2013;21(3):448–455.
Piccinini AM, Midwood KS. DAMPening inflammation by modulating TLR signaling. Mediators Inflamm. 2010. doi:10.1155/2010/672395.
Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197–216.
Kenny EF, O’Neill LAJ. Signaling adaptors used by toll-like receptors: an update. Cytokine. 2008;43(3):342–349.
Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13:1324–1332.
Isayama F, Hines IN, Kremer M, et al. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol Gastrointest Liver Physiol.
2006;290:1318–1328.
Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology. 2007;46:297–306. Watanabe A, Hashmi A, Gomes DA, et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology. 2007;46:1509–1518.
Seki E, Tsutsui H, Iimuro Y, et al. Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration. Hepatology. 2005;41:443–450.
Riad A, Jager S, Sobirey M, et al. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol. 2008;180:6954– 6961.
65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84.
disease. Nat Clin Pract Cardiovasc Med. 2007;4:444–454.
Wolf G, Bohlender J, Bondeva T, et al. Angiotensin II upregulates toll-like receptor 4 on mesangial cells. J Am Soc Nephrol. 2006;17:1585–1593.
Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by toll-like receptors and hyaluronan. Nat Med. 2005;11:1173–1179.
Michelsen KS, Wong MH, Shah PK, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA. 2004;101:10679–10684. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by toll-like receptor 2. J Clin Invest. 2005;115:3149–156.
Wang J, Hori K, Ding J, et al. Toll-like receptors expressed by dermal fibroblasts contribute to hypertrophic scarring. J Cell Physiol. 2011;226(5):1265–1273.
Babelova A, Moreth K, Tsalastra-Greul W, et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via Toll-like and P2X receptors. J Biol Chem.
2009;284(36):24035–24048.
Schaefer L, Babelova A, Kiss E, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest.
2005;115(8):2223–2233.
Shimazu R, Akashi S, Ogata H, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 1999;189(11):1777–1782.
Jin MS, Lee J-O. Structures of the Toll-like receptor family and its ligand complexes. Immunity. 2008;29(2):182–191.
Bucala R, Spiegel LA, Chesney J, et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994; 1: 71–81.
Pilling D, Fan T, Huang D, et al. Identification of markers that distinguish monocyte- derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One.
2009;4:e7475.
Quan TE, Cowper S, Wu SP, et al. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol. 2004;36:598–606.
Direkze NC, Hodivala-Dilke K, Jeffery R, et al. Bone marrow contribution to tumor- associated myofibroblasts and fibroblasts. Cancer Res. 2004;64:8492–8495.
Maharaj S, Shimbori C, Kolb M. Fibrocytes in pulmonary fibrosis: a brief synopsis. Eur Respir Rev. 2013;22(130):552–557.
Kuwana M, Okazaki Y, Kodama H, et al. Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol. 2003;74:833– 845.
Abe R, Donnelly SC, Peng T, et al. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol. 2001;166:7556–7562.
Strieter RM, Keeley EC, Hughes MA, et al. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J Leukoc Biol. 2009;86:1111– 1118.
Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep. 2006;8(2):145–150.
Yang L Shankowsky HA, Scott PG, et al. Peripheral blood fibrocytes from burn patients: identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells. Lab Invest. 2002;82:1183–1192.
Yang L, Jiao H, Shankowsky HA, et al. Identification of fibrocytes in post-burn hypertrophic scar. Wound Repair Regen. 2005;13(4):398–404.
85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104.
Wang J, Jiao H, Stewart TL, et al. Accelerated wound healing in leukocyte-specific, protein 1-deficient mouse is associated with increased infiltration of leukocytes and fibrocytes. J Leukoc Biol. 2007;82:1554–1563.
Wang J, Stewart TL, Chen H, et al. Improved scar in post-burn patients following interferon alpha 2b treatment is associated with decreased angiogenesis mediated by vascular endothelial cell growth factor. J Interferon Cytokine Res. 2008;28(7):423–434. Wang J, Jiao H, Stewart TL, et al. Improvement in postburn hypertrophic scar after
treatment with IFN-alpha2b is associated with decreased fibrocytes. J Interferon Cytokine Res. 2007;27:921–930.
Wang JF, Jiao H, Stewart TL, et al. Fibrocytes from burn patients regulate the activities of fibroblasts. Wound Repair Regen. 2007;15(1):113–121.
Roufosse C, Bou-Gharios G, Prodromidi E, et al. Bone marrow-derived cells do not
contribute significantly to collagen I synthesis in a murine model of renal fibrosis. J Am Soc Nephrol. 2006;17:775–782.
Barisic-Dujmovic T, Boban I, Clark SH. Fibroblasts/myofibroblasts that participate in cutaneous wound healing are not derived from circulating progenitor cells. J Cell Physiol. 2010;222(3):703–712.
Higashiyama R, Nakao S, Sibusawa Y, et al. Differential contribution of dermal resident and bone marrow-derived cells to collagen production during wound healing and fibrogenesis. J Invest Dermatol. 2011;131(2):529–536.
Antoniou KM, Soufla G, Lymbouridou R, et al. Expression analysis of angiogenic growth factors and biological axis CXCL12/CXCR4 axis in idiopathic pulmonary fibrosis. Connect Tissue Res. 2010;51:71–80.
Chen HC, Yang JY, Chuang SS, et al. Heterotopic ossification in burns: our experience and literature reviews. Burns. 2009;35(6):857–862.
Evans EB. Heterotopic bone formation in thermal burns. Clin Orthop Relat Res. 1991; (263):94–101.
Tsionos I, Leclercq C, Rochet JM. Heterotopic ossification of the elbow in patients with burns. Results after early excision. J Bone Joint Surg Br. 2004;86(3):396–403.
Gaur A, Sinclair M, Caruso E, et al. Heterotopic ossification around the elbow following burns in children: results after excision. J Bone Joint Surg Am. 2003;85A(8):1538–1543. Michelsson JE, Rauschning W. Pathogenesis of experimental heterotopic bone formation following temporary forcible exercising of immobilized limbs. Clin Orthop Relat Res. 1983;176:265–272.
Medina A, Shankowsky HA, Savaryn B, et al. Characterization of heterotopic ossification in burn patients. J Burn Care Res. 2014;35(3):448–455.
Zuo KJ, Tredget EE. Multiple Marjolin’s ulcers arising from irradiated post-bun hypertrophic scars: a case report. Burns. 2014;40(4):e21–e215.
Medina A, Ma Z, Varkey M, et al. Fibrocytes participate in the development of heterotopic ossification. J Burn Care Res. 2015;35(3):251–256.
Choi YH, Burdick MD, Strieter RM. Human circulating fibrocytes have the capacity to differentiate osteoblasts and chondrocytes. Int J Biochem Cell Biol. 2010;42(5):662–671. Medina A, Ghahary A. Reprogrammed fibrocytes induce a mixed Th1/Th2 cytokine response of naïve CD4(+) T cells. Mol Cell Biochem. 2011;346(1/2):89–94.
Miller AC, Rashid RM, Elamin EM. The "T" in trauma: the helper T-cell response and the role of immunomodulation in trauma and burn patients. J Trauma. 2007;63(6):1407–1417. Tredget EE, Yang L, Delehanty M, et al. Polarized T helper cells Th2 cytokine production in patients with hypertrophic scar following thermal injury. J Interferon Cytokine Res.
105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 2006;26:179–189.
Wang J, Jiao H, Stewart TL, et al. Increased TGF-beta-producing CD4+ T lymphocytes in postburn patients and their potential interaction with dermal fibroblasts in hypertrophic scarring. Wound Repair Regen. 2007;15(4):530–539.
MacConmara MP, Maung AA, Fujimi S, et al. Increased CD4+ CD25+ T regulatory cell activity in trauma patients depresses protective Th1 immunity. Ann Surg. 2006;244:514– 523.
Shao DD, Suresh R, Vakil V, et al. Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J Leukoc Biol. 2008;83:1323–1333. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13:1324–1332.
Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis. 2010;30(3):245–257.
Barron L, Wynn TA. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol. 2011;300(5):723–728.
Montazi M, Ding J, Kwan P, et al. Morphologic and histologic comparison of hypertrophic scar in nude mice, T-cell receptor and recombination activating gene knockout mice. Plast Reconstr Surg. 2015;136(6):1192–1204.
Zhu Z, Ding J, Tredget EE. The molecular basis of hypertrophic scars. Burns Trauma. 2016; 4:2.
Nagaoka T, Kaburagi Y, Hamaguchi Y, et al. Delayed wound healing in the absence of intercellular adhesion molecule-1 or L-selectin expression. Am J Pathol. 2000;157:237–247. Eming SA, Werner S, Bugnon P, et al. Accelerated wound closure in mice deficient for interleukin-10. Am J Pathol. 2007;170:188–202.
Mahdavian Delavary B, van der Veer WM, van Egmond M, et al. Macrophages in skin injury and repair. Immunobiology. 2011;216:753–762.
Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4:583– 594.
Song E, Ouyang N, Horbelt M, et al. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol. 2000;204:19–28. Mills CD, Kincaid K, Alt JM, et al. M1/M2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166–6173.
Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677–686.
Martinez FO, Sica A, Mantovani A, et al. Macrophage activation and polarization. Front Biosci. 2008;13:453–461.
Grinberg S, Hasko G, Wu D, et al. Suppression of PLC β2 by endotoxin plays a role in the adenosine A(2A) receptor-mediated switch of macrophages from an inflammatory to an angiogenic phenotype. Am J Pathol. 2009;175:2439–2453.
Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122:787–795.
Zhu Z, Ding J, Ma Z, et al. The natural behavior of mononuclear phagocytes in HTS formation. Wound Repair Regen. 2015. doi:10. 1111/wrr.12378.
Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Annu Rev Biochem 1998;67:227–264.
Platanias LC. Interferons: laboratory to clinic investigations. Curr Opin Oncol 1995;7(6):560–565.
126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146.
Tredget EE, Shankowsky HA, Pannu R, et al. Transforming growth factor-beta in thermally injured patients with hypertrophic scars: effects of interferon alpha-2a. Plast Reconstr Surg. 1998;102(5):1317–1328.
Ghahary A, Shen YJ, Scott PG, et al. Immunolocalization of TGF-beta 1 in human hypertrophic scar and normal dermal tissues. Cytokine. 1995;7:184–190.
Wang R, Ghahary A, Dodd, C, et al. Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-beta1 mRNA and protein than normal skin and cells. Wound Repair Regen. 2009;8:128–137.
Berman B, Viera MH, Amini S, et al. Prevention and management of hypertrophic scars and keloids after burns in children. J Craniofac Surg. 2008;19(4):989–1006.
Wong TW, Chiu HC, Yip KM. Intralesional interferon alpha-2b has no effect in the treatment of keloids. Br J Dermatol. 1994;130(5):683–685.
Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis c who failed interferon-alfa/ribavirin therapy. Gastroenterology. 2009;136(5):1618–1628.
Yang YF, Zhao W, Zhong YD, et al. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat. 2009;16(4):265–271.
Rees PA, Greaves NS, Baguneid M, et al. Chemokines in wound healing and as potential therapeutic targets for reducing cutaneous scarring. Adv Wound Care. 2015;4(11):687–703. Xu J, Mora A, Shim H, et al. Role of the SDF-1/CXCR4 axis in the pathogenesis of lung injury and fibrosis. Am J Respir Cell Mol Biol. 2007;37(3):291–299.
Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998;393(6685):595–599.
Nagasawa T. Role of chemokine SDF-1/PBSF and its receptor CXCR4 in blood vessel development. Ann N Y Acad Sci. 2001;947:112–115.
Avniel S, Arik Z, Maly A, et al. Involvement of the CXCL12/CXCR4 pathway in the recovery of skin following burns. J Invest Dermatol. 2006;126(2):468–476.
Ding J, Ma Z, Liu H, et al. The therapeutic potential of a C-X-C chemokine receptor type 4 (CXCR-4) antagonist on hypertrophic scarring in vivo. Wound Repair Regen.
2014;22(5);622–630.
Jarvinen TAH, Ruoshlahti E. Targeted antiscarring therapy for tissue injuries. Adv Wound Care. 2015;2(5):51–55.
Jarvinen TAH, Ruoshlahti E. Target seeking antifibrotic compound enhances wound healing and suppresses scar formation. Proc Natl Acad Sci USA. 2010;107:21671–21676.
Kwan P, Ding J, Tredget EE. MicroRNA 181b regulates decorin production by dermal fibroblasts and may be a potential therapy for hypertrophic scar. PLoS One.
205;10(4):e0123054.
Heimbach D, Engrav L, Grube B, et al. Burn depth: a review. World J Surg.